Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes

Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes

2011 Asia Pac. J. Clin. Oncol

Chang, G.C. | Ahn, M.J. | Wright, E. | Kim, H.T. | Kim, J.H. | Kang, J.H. | Kim, S.W. | Sherman, S. | Walzer, S. | Volume: 7 Suppl 2, Issue: , Pages: 34-40, administration & dosage, Adult, Aged, Aged,80 and over, analogs & derivatives, analysis, Antibodies,Monoclonal, Antibodies,Monoclonal,Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma,Non-Small-Cell Lung, Cisplatin, Disease-Free Survival, drug therapy, Far East, Female, Glutamates, Guanine, Humans, Lung Neoplasms, Male, methods, Middle Aged, Performance, Safety, Survival, Survival Analysis, therapeutic use, therapy, Treatment Outcome, Young Adult,

AIM: To indirectly compare real-life clinical effectiveness of bevacizumab + cisplatin-based therapy from the Safety of Avastin in Lung (SAiL) phase IV clinical trial with published evidence from the phase III clinical trial for pemetrexed + cisplatin among East Asian patients with non-squamous metastatic or recurrent non-small cell lung cancer (NSCLC). METHODS: Survival outcomes were compared between subgroups of East Asian patients receiving treatments of either bevacizumab + cisplatin-based chemotherapy or pemetrexed + cisplatin using a matching-adjusted indirect comparison approach. Patient-level data were used to derive a new group with similar characteristics compared to those reported in a phase III clinical trial evaluating pemetrexed + cisplatin therapy. Exclusions to the SAiL data included those with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2, those with mixed cell histology, non-East Asians and those who did not receive cisplatin-based chemotherapy. In total 1000 samples of the pre-matched analysis set of the SAiL data were selected that resulted in equal distributions of the ECOG PS and gender matching variables selected and evaluated for a progression-free survival (PFS) outcome. RESULTS: Median PFS was longer for patients treated with bevacizumab-based therapy (7.4 months; 95% confidence interval [CI]: 6.7-8.2) versus pemetrexed + cisplatin (6.4 months; 95% CI N/A) among non-squamous East Asian NSCLC patients. CONCLUSION: The results suggest that East Asian non-squamous NSCLC patients treated with bevacizumab-based therapy have a trend toward improved PFS outcomes compared to those treated with pemetrexed + cisplatin, even after adjusting for differences between the two trial groups

https://www.doi.org/10.1111/j.1743-7563.2011.01400.x